What is Medpace?
Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace operates as a premier global clinical research organization (CRO). The company specializes in providing comprehensive, core development services that span the entire lifecycle of drug, biologic, and medical device programs. By integrating scientific expertise with operational excellence, Medpace acts as a critical partner for biopharmaceutical companies seeking to streamline their research and development efforts.
The firm's market position is defined by its ability to manage complex, multi-site clinical trials across diverse therapeutic areas. With a focus on high-quality data management, regulatory affairs, and clinical monitoring, Medpace provides the necessary infrastructure for sponsors to achieve efficient trial execution. Their service model is designed to mitigate risk and reduce time-to-market, making them an essential player in the global healthcare innovation ecosystem.
How much funding has Medpace raised?
Medpace has raised a total of $161M across 1 funding round:
Stock Offering
$161M
Stock Issuance/Offering (2016): $161M, investors not publicly disclosed
Key Investors in Medpace
Medpace
Undisclosed investor participating in the funding round.
Medpace
Undisclosed investor participating in the funding round.
Medpace
Undisclosed investor participating in the funding round.
What's next for Medpace?
Looking ahead, the strategic deployment of $161M is expected to catalyze further expansion of Medpace's global footprint and technological capabilities. As the clinical research industry faces increasing pressure to deliver faster results without compromising safety or data integrity, Medpace is well-positioned to invest in advanced digital health solutions and decentralized trial methodologies.
The company's future growth strategy likely involves deepening its therapeutic expertise and enhancing its global site network to support increasingly specialized medical device and biologic programs. By maintaining a focus on operational scalability and scientific rigor, Medpace is poised to sustain its competitive advantage, ensuring it remains a preferred partner for organizations navigating the evolving landscape of global clinical development.
